Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
Pfizer's Revatio injection for the treatment of pulmonary arterial hypertension has been approved by the US Food and Drug Administration.
Pfizer says Revatio is the only FDA-approved phosphodiesterase-5 inhibitor available in both tablet and intravenous formulations.
Revatio is indicated for the treatment of adult patients with pulmonary arterial hypertension to improve exercise ability and delay clinical worsening.
The delay in clinical worsening was demonstrated when Revatio was added to background epoprostenol therapy.
The efficacy of Revatio has not been adequately evaluated in patients taking bosentan concurrently.
Revatio injection is for the continued treatment of patients with pulmonary arterial hypertension who are currently prescribed Revatio tablets but who are temporarily unable to take oral medication.
Story provided by Business Financial Newswire
Life-long Celtic fan Brian Duffy has joined the board as an independent non-executive director.Duffy is group president, Europe, of the Polo Ralp...
Anglo-Swiss mining company Xstrata reported operating EBITDA of $7bn in the year to end-December 2009, despite unprecedented destocking in the fi...
© 2010 The IBTimes Company Ltd. All Rights Reserved.
Partners 
EMAIL
PRINT
RSS
SHARE
